WRassman,M.D. BaldingBlog
    • Menu

    Post-finasteride Syndrome

    Jul 18, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    Post-finasteride syndrome: An emerging clinical problem

    Author links open overlay panelSilviaDiviccaroRoberto CosimoMelcangiSilviaGiatti

    Abstract

    The presence of side effects during pharmacological treatment is unfortunately a quite common problem. In this review, we focused our attention on adverse events related to 5 alpha-reductase (5?-R) inhibitors (i.e., finasteride and dutasteride), approved for the treatment of benign prostatic hyperplasia and androgenetic alopecia (AGA).

    Although these drugs are generally well tolerated, many reports described adverse effects in men during treatment, such as sexual dysfunction and mood alteration. In addition, it has been also reported that persistent side effects may occur in some AGA patients. This condition, termed post-finasteride syndrome (PFS) is characterized by sexual side effects (i.e., low libido, erectile dysfunction, decreased arousal and difficulty in achieving orgasm), depression, anxiety and cognitive complaints that are still present despite drug withdrawal. Indeed, some national agencies (e.g., Swedish Medical Products Agency, the Medicines and Healthcare Products Regulatory Agency of UK and the U.S. Food and Drug Administration) required to include multiple persistent side effects within the finasteride labels.

    As here reported, these observations are mainly based on self-reporting of the symptomatology by the patients and few clinical studies have been performed so far. In addition, molecular mechanisms and/or genetic determinants behind such adverse effects have been poorly explored both in patients and animal models. Therefore, results here discussed indicate that PFS is an emerging clinical problem that needs to be further elucidated.

    This article in full can be found here:  https://www.sciencedirect.com/science/article/pii/S235228951930061X?via%3Dihub#bib122https://www.sciencedirect.com/science/article/pii/S235228951930061X?via%3Dihub#bib122


    http://tau.amegroups.com/article/view/39898/html

    Original Article

    Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia

    Mohit Khera1, Jeffrey K. Than2, James Anaissie1, Ali Antar1, Weitao Song1, Boriss Losso1, Alexander Pastuszak3, Taylor Kohn4, Jorge Rivera Mirabal1

    1Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA; 2Baylor College of Medicine, Houston, TX, USA; 3Division of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA; 4The James Buchanan Brady Urological Institute at Johns Hopkins School of Medicine, Baltimore, MD, USA

    Contributions: (I) Conception and design: All Authors; (II) Administrative support: All authors; (III) Provision of study materials or patients: M Khera; (I) Collection and assembly of data: All authors; (I) Data analysis and interpretation: All authors; (I) Manuscript writing: All authors; (I) Final approval of manuscript: All authors.

    Correspondence to: Mohit Khera, MD. Professor, Scott Department of Urology, Baylor College of Medicine, 7200 Cambridge St, Suite 10B, Houston, Texas 77030, USA. Email: mkhera@bcm.edu.

    Background: The constellation of persistent sexual, neurological, and physical adverse effects in patients who discontinue 5?-reductase inhibitors (5ARIs) has garnered recent concern. The objective of this study was to evaluate potential penile vascular changes and persistent adverse effects of 5ARIs in men treated for androgenic alopecia (AGA).

    Methods: This was a prospective case-control study with 25 subjects with a history of 5ARI use for AGA and 28 controls. Patient self-reported questionnaires including the International Index of Erectile Function (IIEF), International Prostate Symptom Score (IPSS), Patient Health Questionnaire-9 (PHQ-9), the Epworth Sleepiness Scale (ESS) and the Androgen Deficiency in the Aging Male (ADAM) were used. Penile duplex Doppler ultrasound (PDDU) results were evaluated in men with a history of 5ARI use.

    Results: A significant difference in total IIEF score between the 5ARI (median: 35; IQR: 29–43) and control group (median: 29; IQR: 27–32) (P=0.035) was observed. Seventeen 5ARI subjects (68%) had a vascular abnormality on PDDU. The median (IQR) for total IPSS score for the 5ARI group was 10 [5–16] compared to 3 [2–8] for the controls (P<0.01). The 5ARI group had a higher median total PHQ-9 score than controls [10 (6.5–16) vs. 1 (0–2) (P<0.001)]. Two subjects (8%) committed suicide during or after the study.

    Conclusions: While the sexual side effects of 5ARIs are well known, there may be persistent genitourinary, physical, psycho-cognitive, anti-androgenic and penile vascular changes after 5ARI discontinuation. Use of 5ARIs for treatment of AGA may lead to persistent sexual, genitourinary, physical, psycho-cognitive, and anti-androgenic sequelae even after cessation of 5ARI therapy.

    Keywords: Finasteride; penile duplex Doppler; major depressive disorder; hypogonadism; erectile dysfunction (ED)


    https://wjmh.org/search.php?where=aview&id=10.5534/wjmh.200012&code=2074WJMH&vmode=FULL

    Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm
    Abdulmaged M. Traish
    Department of Urology, Boston University School of Medicine, Boston, MA, USA.

     

    Abstract
    5?-dihydrotestosterone (5?-DHT) is the most potent natural androgen. 5?-DHT elicits a multitude of physiological actions, in a host of tissues, including prostate, seminal vesicles, hair follicles, skin, kidney, and lacrimal and meibomian glands. However, the physiological role of 5?-DHT in human physiology, remains questionable and, at best, poorly appreciated. Recent emerging literature supports a role for 5?-DHT in the physiological function of liver, pancreatic ?-cell function and survival, ocular function and prevention of dry eye disease and kidney physiological function. Thus, inhibition of 5?-reductases with finasteride or dutasteride to reduce 5?-DHT biosynthesis in the course of treatment of benign prostatic hyperplasia (BPH) or male pattern hair loss, known as androgenetic alopecia (AGA) my induces a novel form of tissue specific androgen deficiency and contributes to a host of pathophysiological conditions, that are yet to be fully recognized. Here, we advance the concept that blockade of 5?-reductases by finasteride or dutasteride in a mechanism-based, irreversible, inhabitation of 5?-DHT biosynthesis results in a novel state of androgen deficiency, independent of circulating testosterone levels. Finasteride and dutasteride are frequently prescribed for long-term treatment of lower urinary tract symptoms in men with BPH and in men with AGA. This treatment may result in development of non-alcoholic fatty liver diseases (NAFLD), insulin resistance (IR), type 2 diabetes (T2DM), dry eye disease, potential kidney dysfunction, among other metabolic dysfunctions. We suggest that long-term use of finasteride and dutasteride may be associated with health risks including NAFLD, IR, T2DM, dry eye disease and potential kidney disease.

    Reader Comments0

    Share this entry
    • Share on Facebook
    • Share on Twitter
    Newer Entries Older Entries

    Leave a Comment

    Want to join the discussion? Feel free to contribute! Note: We do not tolerate offensive language or personal attacks to other readers. Marketing links or commercial advertisements will be deleted.

    Leave a Reply Cancel reply

    Your email address will not be published. Required fields are marked *

    ( Will not be published )

    + =

    Videos

    Podcasts

    Ask Dr. Rassman

    * Your questions may be published (without your contact information).

    [contact-form-7 id=”27935″ title=”Sidebar Contact”]

    Over 21 million women and 35 million men in America suffer from hair loss. For many of these people, the psychological impact on their life is debilitating.

    Dr. Rassman is a world leading expert in hair loss with over 25 years of experience and over 50,000 satisfied clients.

    About

    This site exists to educate about hair loss and hair restoration.

    William R. Rassman, M.D.

    Categories

    • ACell
    • African American
    • Age
    • April Fools
    • Density
    • Diseases
    • Drugs
    • Drugs (Cause Hair Loss)
    • Favorites
    • Female Hair Loss
    • FUE
    • Hair Cloning
    • Hair Loss Causes
    • Hair Pieces / Systems
    • Hair Products
    • Hair Transplantation
    • Hairlines
    • Megasession
    • Other
    • Other Surgical Procedures
    • Personal Stories
    • Photos
    • Pigments
    • Podcasts
    • Post-Operative
    • Repair
    • Repost
    • Scalp MicroPigmentation
    • Scarring
    • Thinning
    • Tidbits
    • Training
    • Videos

    Archives

    • December 2023
    • November 2023
    • October 2023
    • September 2023
    • August 2023
    • July 2023
    • June 2023
    • May 2023
    • April 2023
    • March 2023
    • February 2023
    • January 2023
    • December 2022
    • November 2022
    • October 2022
    • September 2022
    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • November 2021
    • October 2021
    • September 2021
    • August 2021
    • July 2021
    • June 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018
    • December 2017
    • November 2017
    • October 2017
    • September 2017
    • August 2017
    • July 2017
    • June 2017
    • May 2017
    • April 2017
    • March 2017
    • February 2017
    • January 2017
    • December 2016
    • November 2016
    • October 2016
    • June 2016
    • May 2016
    • April 2016
    • March 2016
    • February 2016
    • January 2016
    • December 2015
    • November 2015
    • October 2015
    • September 2015
    • August 2015
    • July 2015
    • June 2015
    • May 2015
    • April 2015
    • March 2015
    • February 2015
    • January 2015
    • December 2014
    • November 2014
    • October 2014
    • September 2014
    • August 2014
    • July 2014
    • June 2014
    • May 2014
    • April 2014
    • March 2014
    • February 2014
    • January 2014
    • December 2013
    • November 2013
    • October 2013
    • September 2013
    • August 2013
    • July 2013
    • June 2013
    • May 2013
    • April 2013
    • March 2013
    • February 2013
    • January 2013
    • December 2012
    • November 2012
    • October 2012
    • September 2012
    • August 2012
    • July 2012
    • June 2012
    • May 2012
    • April 2012
    • March 2012
    • February 2012
    • January 2012
    • December 2011
    • November 2011
    • October 2011
    • September 2011
    • August 2011
    • July 2011
    • June 2011
    • May 2011
    • April 2011
    • March 2011
    • February 2011
    • January 2011
    • December 2010
    • November 2010
    • October 2010
    • September 2010
    • August 2010
    • July 2010
    • June 2010
    • May 2010
    • April 2010
    • March 2010
    • February 2010
    • January 2010
    • December 2009
    • November 2009
    • October 2009
    • September 2009
    • August 2009
    • July 2009
    • June 2009
    • May 2009
    • April 2009
    • March 2009
    • February 2009
    • January 2009
    • December 2008
    • November 2008
    • October 2008
    • September 2008
    • August 2008
    • July 2008
    • June 2008
    • May 2008
    • April 2008
    • March 2008
    • February 2008
    • January 2008
    • December 2007
    • November 2007
    • October 2007
    • September 2007
    • August 2007
    • July 2007
    • June 2007
    • May 2007
    • April 2007
    • March 2007
    • February 2007
    • January 2007
    • December 2006
    • November 2006
    • October 2006
    • September 2006
    • August 2006
    • July 2006
    • June 2006
    • May 2006
    • April 2006
    • March 2006
    • February 2006
    • January 2006
    • December 2005
    • November 2005
    • October 2005
    • September 2005
    • August 2005
    • July 2005
    • June 2005
    • May 2005
    • April 2005
    • June 202
    • May 202

    Links

    Disclaimer

    This site is intended to educate the public on hair loss topics based on personal experience and opinions from Dr. William Rassman and contributing physician editors. Information provided on BaldingBlog.com should not be used for the purpose of medical diagnosis or treatment.

    Scroll to top